Schizophrenia Research最新文献

英文中文

Corrigendum to “Jang YJ, et al. Characterizing the relationship between personality dimensions and psychosis-specific clinical characteristics” [Schizophr Res. 276 (2025) 88–96 10.1016/j.schres.2025.01.002 (Epub ahead of print, PMID: 39864301, Jan 25)] “张玉杰等”的勘误表。人格维度与精神病特异性临床特征的关系表征[j].精神分裂症。276 (2025)88-96 10.1016/j.schres. 2015.01.002 （Epub ahead of print, PMID: 39864301, 1月25日）。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 DOI: 10.1016/j.schres.2025.05.005

Y.J. Jang , W. Yassin , R. Mesholam-Gately , E.S. Gershon , S. Keedy , G.D. Pearlson , C.A. Tamminga , J. McDowell , D.A. Parker , K. Sauer , B. Clementz , M.S. Keshavan

引用次数: 0

The hippocampus: At the nexus of risk and resilience for schizophrenia 海马体：精神分裂症风险和恢复力的关系

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-09-23 DOI: 10.1016/j.schres.2025.09.016

Katherine S.F. Damme

引用次数: 0

Does adjunctive electro-convulsive therapy improve the speed of treatment response in schizophrenia? A systematic review and week-by-week meta-analyses of controlled clinical trials 辅助电痉挛治疗是否能提高精神分裂症的治疗反应速度？对照临床试验的系统回顾和每周荟萃分析。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-09-17 DOI: 10.1016/j.schres.2025.08.018

Makarand Pantoji, Srinivas Balachander, Palash Prajapati, Shyam Sundar Arumugham, Ganesan Venkatasubramanian, Jagadisha Thirthalli

Background

Electroconvulsive therapy (ECT) is sometimes recommended in patients with schizophrenia to hasten clinical response. However, there is limited research comparing the speed of response between ECT in combination with antipsychotic medication versus antipsychotics alone. We conducted a systematic review and meta-analyses of week-by-week clinical response to examine whether ECT augmentation leads to faster improvement in psychotic symptoms in patients with schizophrenia.

Methods

We searched PubMed/Medline and Cochrane Library for controlled trials which compared the combination of ECT and antipsychotic drugs (ECT + AP) with antipsychotic drugs alone (AP) in patients with schizophrenia. We performed a pairwise random-effects meta-analysis for each time point. Hedge's g was used as the effect size estimate. A multivariate mixed-effects meta-analysis was performed to test whether the response speed was different between the groups.

Results

Of a total of 4899 search results, 12 studies were included. In five of them, the authors reported that the ECT + AP group responded faster. Pairwise meta-analysis for each week showed that ECT + AP group was significantly superior to the AP group at week 1 [g = 0.897 (95 % CI 0.236–1.557)], week 2 [g = 0.986 (95 % CI 0.273–1.700)], and week 4 [g = 1.587 (95 % CI 0.180–2.995)], but not after that. The multivariate mixed-effects meta-analysis also showed a significant Group*Week interaction [B = 0.17(95 % CI 0.10–0.24), p < 0.001].

Conclusions

ECT augmentation in schizophrenia, given its potential for faster response, may have some advantage in acutely ill patients, particularly those requiring hospitalization and needing rapid symptom resolution.

背景：电痉挛疗法（ECT）有时被推荐用于精神分裂症患者，以加速临床反应。然而，比较ECT联合抗精神病药物与单独抗精神病药物的反应速度的研究有限。我们对每周的临床反应进行了系统回顾和荟萃分析，以检验ECT增强是否能更快地改善精神分裂症患者的精神病症状。方法：检索PubMed/Medline和Cochrane Library，检索比较ECT联合抗精神病药物（ECT + AP）与单独抗精神病药物（AP）治疗精神分裂症患者的对照试验。我们对每个时间点进行两两随机效应荟萃分析。使用Hedge’s g作为效应量估计。采用多变量混合效应meta分析检验两组间反应速度是否存在差异。结果：在4899个检索结果中，纳入了12项研究。在其中的5例中，作者报告说ECT + AP组反应更快。各周的两两荟萃分析显示，ECT + AP组在第1周[g = 0.897 (95% CI 0.236-1.557)]、第2周[g = 0.986 (95% CI 0.273-1.700)]和第4周[g = 1.587 (95% CI 0.180-2.995)]显著优于AP组，之后则无显著差异。多变量混合效应荟萃分析也显示了显著的组与周相互作用[B = 0.17(95% CI 0.10-0.24), p]。结论：ECT增强治疗精神分裂症，鉴于其潜在的更快的反应，可能对急症患者有一些优势，特别是那些需要住院治疗和需要快速缓解症状的患者。

{"title":"Does adjunctive electro-convulsive therapy improve the speed of treatment response in schizophrenia? A systematic review and week-by-week meta-analyses of controlled clinical trials","authors":"Makarand Pantoji, Srinivas Balachander, Palash Prajapati, Shyam Sundar Arumugham, Ganesan Venkatasubramanian, Jagadisha Thirthalli","doi":"10.1016/j.schres.2025.08.018","DOIUrl":"10.1016/j.schres.2025.08.018","url":null,"abstract":"<div><h3>Background</h3><div>Electroconvulsive therapy (ECT) is sometimes recommended in patients with schizophrenia to hasten clinical response. However, there is limited research comparing the speed of response between ECT in combination with antipsychotic medication versus antipsychotics alone. We conducted a systematic review and meta-analyses of week-by-week clinical response to examine whether ECT augmentation leads to faster improvement in psychotic symptoms in patients with schizophrenia.</div></div><div><h3>Methods</h3><div>We searched PubMed/Medline and Cochrane Library for controlled trials which compared the combination of ECT and antipsychotic drugs (ECT + AP) with antipsychotic drugs alone (AP) in patients with schizophrenia. We performed a pairwise random-effects meta-analysis for each time point. Hedge's g was used as the effect size estimate. A multivariate mixed-effects meta-analysis was performed to test whether the response speed was different between the groups.</div></div><div><h3>Results</h3><div>Of a total of 4899 search results, 12 studies were included. In five of them, the authors reported that the ECT + AP group responded faster. Pairwise meta-analysis for each week showed that ECT + AP group was significantly superior to the AP group at week 1 [g = 0.897 (95 % CI 0.236–1.557)], week 2 [g = 0.986 (95 % CI 0.273–1.700)], and week 4 [g = 1.587 (95 % CI 0.180–2.995)], but not after that. The multivariate mixed-effects meta-analysis also showed a significant Group*Week interaction [B = 0.17(95 % CI 0.10–0.24), <em>p</em> < 0.001].</div></div><div><h3>Conclusions</h3><div>ECT augmentation in schizophrenia, given its potential for faster response, may have some advantage in acutely ill patients, particularly those requiring hospitalization and needing rapid symptom resolution.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"285 ","pages":"Pages 114-123"},"PeriodicalIF":3.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Longitudinal analysis of absolute neutrophil count (ANC) variability and neutropenia incidence in African American schizophrenia patients by ACKR1 genotype 非裔美国人精神分裂症患者ACKR1基因型绝对中性粒细胞计数（ANC）变异性和中性粒细胞减少发生率的纵向分析

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-09-18 DOI: 10.1016/j.schres.2025.09.011

Sonja Xie , Matthew Glassman , Gopal Vyas , Evaristus Nwulia , Deanna L. Kelly

Background

About 30–50 % of schizophrenia patients are unresponsive to treatment. Clozapine is the only FDA-approved antipsychotic for treatment-resistant schizophrenia (TRS) but is disproportionally underutilized in African American populations due to concern over clozapine-induced neutropenia (absolute neutrophil count [ANC] < 1500 cells/mm³). Healthy Black individuals have a lower normative ANC, associated with the “ACKR1-null” CC genotype (SNP rs2814778) and termed Benign Ethnic Neutropenia (BEN).

Methods

To elucidate clozapine risk in this population, we characterized the natural ANC progression in 72 African American schizophrenia patients over 7-weeks to establish a necessary baseline for comparison. Weekly blood tests and TaqMan PCR genotyping were performed. Mixed-effects models (MEM) assessed ANC variability and multinomial logistic regression analyzed neutropenia incidence. Factors included ACKR1 genotype, age, sex, and study site. Medication effects (lithium, antidepressants, anticholinergics, anticonvulsants) on ANC were assessed using generalized estimating equations (GEE).

Results

51/72 participants (70.83 %) were ACKR1-null, exhibiting significantly lower ANC (2800.80 ± 1425.87) compared to the CT/TT group (4958.72 ± 1900.30) (p = 3.99 × 10⁻¹⁵). Neutropenia was more prevalent in the ACKR1-null group (31.4 % [16/51]) compared to the CT/TT group (0 % [0/21]) (p = 0.004), and participants with neutropenia averaged 2.1 ± 1.6 episodes over the 7-week period. Lithium was significantly correlated with higher ANC (p < 0.001). Antidepressant effects varied by genotype, increasing ANC in C-type (p = 0.007) and decreasing ANC in T-type (p < 0.001).

Conclusions

Findings suggest that nearly one-third of healthy African Americans experience neutropenia without clozapine-use. Baseline ANC resembles levels seen during clozapine, reinforcing its safety for broader utilization.

背景：大约30- 50%的精神分裂症患者对治疗无反应。氯氮平是fda批准的唯一用于治疗难治性精神分裂症（TRS）的抗精神病药物，但由于担心氯氮平引起的中性粒细胞减少症（绝对中性粒细胞计数[ANC] 3），在非裔美国人群中使用不足。健康黑人个体具有较低的标准ANC，与“ACKR1-null”CC基因型（SNP rs2814778）相关，称为良性种族中性粒细胞减少症（BEN）。方法：为了阐明氯氮平在这一人群中的风险，我们对72名非裔美国人精神分裂症患者在7周内的ANC自然进展进行了描述，以建立必要的基线进行比较。每周进行血液检测和TaqMan PCR基因分型。混合效应模型（MEM）评估了ANC的变异性，多项逻辑回归分析了中性粒细胞减少症的发生率。影响因素包括ACKR1基因型、年龄、性别和研究地点。使用广义估计方程（GEE）评估药物（锂、抗抑郁药、抗胆碱能药、抗惊厥药）对ANC的影响。结果：51/72例（70.83%）患者ackr1为零，ANC（2800.80±1425.87）明显低于CT/TT组（4958.72±1900.30）（p = 3.99 × 10-15）。中性粒细胞减少在ACKR1-null组（31.4%[16/51]）比CT/TT组（0%[0/21]）更为普遍（p = 0.004），中性粒细胞减少的参与者在7周内平均发作2.1±1.6次。结论：研究结果表明，近三分之一的健康非裔美国人在不使用氯氮平的情况下出现中性粒细胞减少症。基线ANC与氯氮平期间的水平相似，加强了其广泛应用的安全性。

{"title":"Longitudinal analysis of absolute neutrophil count (ANC) variability and neutropenia incidence in African American schizophrenia patients by ACKR1 genotype","authors":"Sonja Xie , Matthew Glassman , Gopal Vyas , Evaristus Nwulia , Deanna L. Kelly","doi":"10.1016/j.schres.2025.09.011","DOIUrl":"10.1016/j.schres.2025.09.011","url":null,"abstract":"<div><h3>Background</h3><div>About 30–50 % of schizophrenia patients are unresponsive to treatment. Clozapine is the only FDA-approved antipsychotic for treatment-resistant schizophrenia (TRS) but is disproportionally underutilized in African American populations due to concern over clozapine-induced neutropenia (absolute neutrophil count [ANC] < 1500 cells/mm<sup>3</sup>). Healthy Black individuals have a lower normative ANC, associated with the “ACKR1-null” CC genotype (SNP rs2814778) and termed Benign Ethnic Neutropenia (BEN).</div></div><div><h3>Methods</h3><div>To elucidate clozapine risk in this population, we characterized the natural ANC progression in 72 African American schizophrenia patients over 7-weeks to establish a necessary baseline for comparison. Weekly blood tests and TaqMan PCR genotyping were performed. Mixed-effects models (MEM) assessed ANC variability and multinomial logistic regression analyzed neutropenia incidence. Factors included ACKR1 genotype, age, sex, and study site. Medication effects (lithium, antidepressants, anticholinergics, anticonvulsants) on ANC were assessed using generalized estimating equations (GEE).</div></div><div><h3>Results</h3><div>51/72 participants (70.83 %) were ACKR1-<em>null</em>, exhibiting significantly lower ANC (2800.80 ± 1425.87) compared to the CT/TT group (4958.72 ± 1900.30) (<em>p</em> = 3.99 × 10<sup>−15</sup>). Neutropenia was more prevalent in the ACKR1-<em>null</em> group (31.4 % [16/51]) compared to the CT/TT group (0 % [0/21]) (<em>p</em> = 0.004), and participants with neutropenia averaged 2.1 ± 1.6 episodes over the 7-week period. Lithium was significantly correlated with higher ANC (<em>p</em> < 0.001). Antidepressant effects varied by genotype, increasing ANC in C-type (<em>p</em> = 0.007) and decreasing ANC in T-type (p < 0.001).</div></div><div><h3>Conclusions</h3><div>Findings suggest that nearly one-third of healthy African Americans experience neutropenia without clozapine-use. Baseline ANC resembles levels seen during clozapine, reinforcing its safety for broader utilization.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"285 ","pages":"Pages 124-131"},"PeriodicalIF":3.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study” [Schizophr Res. 255 (2023) 195–202] “棕榈酸帕利哌酮与口服抗精神病药物治疗对新近发作的精神分裂症患者额叶皮质内髓磷脂体积的影响：来自DREaM研究的磁共振成像结果”[精神分裂症，255(2023)195-202]。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-06-06 DOI: 10.1016/j.schres.2025.05.023

T.A. Tishler, B.M. Ellingson, G. Salvadore, P. Baker, I. Turkoz, K.L. Subotnik, C. de la Fuente-Sandoval, K.H. Nuechterlein, L. Alphs

引用次数: 0

Association between the exposome score for schizophrenia and functioning in remitted first-episode psychosis: results from the HAMLETT study 精神分裂症暴露评分与缓解首发精神病功能之间的关系：来自HAMLETT研究的结果。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-10-06 DOI: 10.1016/j.schres.2025.09.023

Sterre Kamphuis , Angelo Arias-Magnasco , Shiral Gangadin , Marieke Begemann , Ben Wijnen , Wim Veling , Lieuwe de Haan , HAMLETT-OPHELIA Consortium, Iris Sommer , Jim van Os , P. Roberto Bakker , Sinan Gülöksüz

Background

Environmental risk factors contribute to functional impairment, which can persist even after symptomatic remission of a first episode of psychosis (FEP). To quantify this effect, we calculated the association between exposome score for schizophrenia (ES-SCZ), a cumulative environmental liability score, and functioning in remitted FEP patients.

Methods

Data of 286 participants were derived from the HAMLETT study. General functioning was assessed using the Global Assessment of Functioning (GAF) scale at baseline, when participants were in remission for 3–6 months. ES-SCZ was calculated based on previously validated estimates and included childhood adversity domains (emotional and physical neglect; emotional, physical and sexual abuse; and bullying), cannabis use, hearing impairment, and winter birth. The association between ES-SCZ and GAF was evaluated in three multiple linear regression models, with each successive model including additional covariates.

Results

ES-SCZ was negatively associated with the GAF score, even after accounting for age, sex at birth, education, migrant status, antipsychotic type, and FEP duration [B = −1.51 (−2.78 to −0.24), p = .022]. This final model explained 8.6 % of the variance (R²) in the GAF score, with ES-SCZ being the primary contributor, accounting for 35.5 % of this explained variance.

Conclusions

This study independently replicated the finding that ES-SCZ predicts general functioning in FEP, showing its potential for forecasting functioning in remitted FEP patients.

背景：环境危险因素有助于功能损害，即使在首次精神病发作（FEP）症状缓解后，功能损害仍可能持续存在。为了量化这种影响，我们计算了精神分裂症的暴露评分（ES-SCZ）、累积环境责任评分与缓解的FEP患者的功能之间的关系。方法：286名参与者的资料来源于HAMLETT研究。当参与者缓解3-6个月时，在基线时使用总体功能评估（GAF）量表评估一般功能。ES-SCZ是根据先前验证的估计计算的，包括童年逆境领域（情感和身体忽视；情感、身体和性虐待；欺凌）、大麻使用、听力障碍和冬季出生。ES-SCZ与GAF之间的关系通过三个多元线性回归模型进行评估，每个连续模型都包含额外的协变量。结果：ES-SCZ与GAF评分呈负相关，即使考虑了年龄、出生性别、教育程度、移民身份、抗精神病药物类型和FEP持续时间[B = -1.51(-2.78至-0.24),p = 0.022]。最终模型解释了GAF评分中8.6%的方差（R2），其中ES-SCZ是主要贡献者，占该解释方差的35.5%。结论：本研究独立地重复了ES-SCZ预测FEP患者一般功能的发现，显示其预测缓解性FEP患者功能的潜力。

{"title":"Association between the exposome score for schizophrenia and functioning in remitted first-episode psychosis: results from the HAMLETT study","authors":"Sterre Kamphuis , Angelo Arias-Magnasco , Shiral Gangadin , Marieke Begemann , Ben Wijnen , Wim Veling , Lieuwe de Haan , HAMLETT-OPHELIA Consortium, Iris Sommer , Jim van Os , P. Roberto Bakker , Sinan Gülöksüz","doi":"10.1016/j.schres.2025.09.023","DOIUrl":"10.1016/j.schres.2025.09.023","url":null,"abstract":"<div><h3>Background</h3><div>Environmental risk factors contribute to functional impairment, which can persist even after symptomatic remission of a first episode of psychosis (FEP). To quantify this effect, we calculated the association between exposome score for schizophrenia (ES-SCZ), a cumulative environmental liability score, and functioning in remitted FEP patients.</div></div><div><h3>Methods</h3><div>Data of 286 participants were derived from the HAMLETT study. General functioning was assessed using the Global Assessment of Functioning (GAF) scale at baseline, when participants were in remission for 3–6 months. ES-SCZ was calculated based on previously validated estimates and included childhood adversity domains (emotional and physical neglect; emotional, physical and sexual abuse; and bullying), cannabis use, hearing impairment, and winter birth. The association between ES-SCZ and GAF was evaluated in three multiple linear regression models, with each successive model including additional covariates.</div></div><div><h3>Results</h3><div>ES-SCZ was negatively associated with the GAF score, even after accounting for age, sex at birth, education, migrant status, antipsychotic type, and FEP duration [B = −1.51 (−2.78 to −0.24), <em>p</em> = .022]. This final model explained 8.6 % of the variance (R<sup>2</sup>) in the GAF score, with ES-SCZ being the primary contributor, accounting for 35.5 % of this explained variance.</div></div><div><h3>Conclusions</h3><div>This study independently replicated the finding that ES-SCZ predicts general functioning in FEP, showing its potential for forecasting functioning in remitted FEP patients.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"285 ","pages":"Pages 223-231"},"PeriodicalIF":3.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychometric validation of social cognition measures in U.S. Hispanic individuals with schizophrenia 美国西班牙裔精神分裂症患者社会认知测量的心理计量学验证

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-09-15 DOI: 10.1016/j.schres.2025.08.012

Ana T. Flores , Concepción Barrio , Lan Yu , Philip D. Harvey , David L. Penn , Shaun M. Eack , Amy Pinkham

Little is known about cross-ethnic differences in the measurement of social cognition in minoritized groups like Hispanics, who account for a significant portion of the U.S population, potentially leading to culturally incongruent interventions. Using data from the Social Cognition Psychometric Evaluation (SCOPE), the current study conducted a cross-ethnic psychometric assessment of four social cognition measures in Hispanics diagnosed with schizophrenia (n = 73) and a non-Hispanic white group (n = 115). Tasks included Bell Lysaker Emotion Recognition Task (BLERT), Penn Emotion Recognition Task (ER-40), The Awareness of Social Inference Test (TASIT) and the Hinting Task. Tasks were evaluated on test-retest reliability, utility as a repeated measure, internal consistency, sensitivity to group differences, and relationship to functional outcomes. Mean differences between ethnic groups were also analyzed. Psychometric properties were largely adequate and comparable across ethnic groups. Mean differences on emotion recognition tasks were not significantly different between ethnic groups. However, Hispanics scored significantly lower on TASIT and the Hinting Task (assessments of theory of mind), potentially indicative of the influence of racial or cultural factors in these measures. Criterion validity also varied between groups. Although there were robust associations with functional capacity and social skills in the Hispanic group, none of the social-cognitive tasks predicted real-world functional outcomes in this group. These findings suggest that caution should be exercised when using social cognition measures to assess Hispanics and making subsequent clinical decisions.

在像西班牙裔这样占美国人口很大一部分的少数族裔群体中，人们对社会认知测量的跨种族差异知之甚少，这可能导致文化不一致的干预。使用社会认知心理测量评估（SCOPE）的数据，本研究对诊断为精神分裂症的西班牙裔（n = 73）和非西班牙裔白人（n = 115）进行了四项社会认知测量的跨种族心理测量评估。任务包括Bell Lysaker情绪识别任务（BLERT）、Penn情绪识别任务（ER-40）、社会推理意识测试（TASIT）和暗示任务。对任务进行测试-重测信度、作为重复测量的效用、内部一致性、对组差异的敏感性以及与功能结果的关系评估。还分析了族群间的平均差异。心理测量特性在很大程度上是足够的，并且在不同种族之间具有可比性。情绪识别任务的平均差异在种族间无显著差异。然而，西班牙裔在TASIT和暗示任务（心理理论评估）上的得分明显较低，这可能表明种族或文化因素在这些措施中的影响。标准效度在各组之间也有差异。尽管在西班牙裔群体中，功能能力和社交技能有很强的相关性，但没有一项社会认知任务能预测这一群体在现实世界中的功能结果。这些发现表明，在使用社会认知测量来评估西班牙裔和做出后续临床决策时应谨慎行事。

{"title":"Psychometric validation of social cognition measures in U.S. Hispanic individuals with schizophrenia","authors":"Ana T. Flores , Concepción Barrio , Lan Yu , Philip D. Harvey , David L. Penn , Shaun M. Eack , Amy Pinkham","doi":"10.1016/j.schres.2025.08.012","DOIUrl":"10.1016/j.schres.2025.08.012","url":null,"abstract":"<div><div>Little is known about cross-ethnic differences in the measurement of social cognition in minoritized groups like Hispanics, who account for a significant portion of the U.S population, potentially leading to culturally incongruent interventions. Using data from the Social Cognition Psychometric Evaluation (SCOPE), the current study conducted a cross-ethnic psychometric assessment of four social cognition measures in Hispanics diagnosed with schizophrenia (n = 73) and a non-Hispanic white group (n = 115). Tasks included Bell Lysaker Emotion Recognition Task (BLERT), Penn Emotion Recognition Task (ER-40), The Awareness of Social Inference Test (TASIT) and the Hinting Task. Tasks were evaluated on test-retest reliability, utility as a repeated measure, internal consistency, sensitivity to group differences, and relationship to functional outcomes. Mean differences between ethnic groups were also analyzed. Psychometric properties were largely adequate and comparable across ethnic groups. Mean differences on emotion recognition tasks were not significantly different between ethnic groups. However, Hispanics scored significantly lower on TASIT and the Hinting Task (assessments of theory of mind), potentially indicative of the influence of racial or cultural factors in these measures. Criterion validity also varied between groups. Although there were robust associations with functional capacity and social skills in the Hispanic group, none of the social-cognitive tasks predicted real-world functional outcomes in this group. These findings suggest that caution should be exercised when using social cognition measures to assess Hispanics and making subsequent clinical decisions.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"285 ","pages":"Pages 95-104"},"PeriodicalIF":3.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145061144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smartphone intervention apps for schizophrenia: A review of the academic literature and app stores 精神分裂症的智能手机干预应用：学术文献和应用商店综述

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-10-03 DOI: 10.1016/j.schres.2025.09.007

Winna Xia , Christine Hau , James Burns , Sean Ryan , Joseph Firth , Jake Lineradon , John Torous

Background

While the interest and use of apps for anxiety and depression accelerated with COVID-19, less is known about the status of apps for people with schizophrenia and psychosis-spectrum disorders. This study aims to offer a comprehensive overview of the research and commercial app marketplaces (Apple, Android) to assess how recent technological advances translate into tools patients can use today.

Methods

In December 2024, we conducted a narrative review for apps related to schizophrenia and coded a brief overview of the studies, eligibility, outcomes and experiences, engagement and features, attrition and adherence, and app availability. We simultaneously conducted a search on the U.S. Google Play and the U.S. Apple App Store for apps denoted in the research literature and other commercially available apps.

Results

The academic literature search yielded 3753 articles, of which 34 were included. Across these 34 studies, 32 unique apps related to schizophrenia and psychosis were featured. A search of the U.S. app marketplaces yielded only one relevant app peer-reviewed in the last decade and that was broadly accessible to patients.

Conclusion

To realize the full clinical utility of these apps, it is essential to shift the focus toward their specific features and functionalities, supported by more rigorous research and follow-up studies. There is a pressing need for greater standardization in outcome measures and record-keeping practices to ensure consistency and reliability across the field. While the number of commercially available apps has increased, the lack of robust, large-scale controlled studies and standardized controls has resulted in inconsistent findings. Findings highlight the importance of conducting more controlled studies and randomized clinical trials with appropriate controls to strengthen the evidence base and guide the effective implementation of digital health interventions in mental health care.

随着COVID-19的出现，人们对应用程序治疗焦虑和抑郁的兴趣和使用加速了，但人们对应用程序治疗精神分裂症和精神病谱系障碍患者的状况知之甚少。本研究旨在全面概述研究和商业应用程序市场（Apple, Android），以评估最近的技术进步如何转化为患者今天可以使用的工具。方法在2024年12月，我们对与精神分裂症相关的应用程序进行了叙述性回顾，并对研究、资格、结果和经验、参与度和特征、流失和依从性以及应用程序可用性进行了简要概述。我们同时在美国谷歌Play和美国苹果应用商店搜索研究文献中提到的应用和其他商业应用。结果共检索学术文献3753篇，其中纳入34篇。在这34项研究中，有32个与精神分裂症和精神病相关的独特应用程序。对美国应用程序市场的搜索显示，在过去十年中，只有一个相关的应用程序经过同行评审，而且患者可以广泛使用。结论为了充分发挥这些应用程序的临床效用，必须将重点转移到它们的具体特征和功能上，并通过更严格的研究和后续研究来支持。迫切需要在结果衡量和记录保存做法方面加强标准化，以确保整个领域的一致性和可靠性。虽然商业应用程序的数量有所增加，但由于缺乏可靠的大规模对照研究和标准化控制，导致研究结果不一致。研究结果强调了开展更多对照研究和具有适当对照的随机临床试验的重要性，以加强证据基础，并指导在精神卫生保健中有效实施数字卫生干预措施。

{"title":"Smartphone intervention apps for schizophrenia: A review of the academic literature and app stores","authors":"Winna Xia , Christine Hau , James Burns , Sean Ryan , Joseph Firth , Jake Lineradon , John Torous","doi":"10.1016/j.schres.2025.09.007","DOIUrl":"10.1016/j.schres.2025.09.007","url":null,"abstract":"<div><h3>Background</h3><div>While the interest and use of apps for anxiety and depression accelerated with COVID-19, less is known about the status of apps for people with schizophrenia and psychosis-spectrum disorders. This study aims to offer a comprehensive overview of the research and commercial app marketplaces (Apple, Android) to assess how recent technological advances translate into tools patients can use today.</div></div><div><h3>Methods</h3><div>In December 2024, we conducted a narrative review for apps related to schizophrenia and coded a brief overview of the studies, eligibility, outcomes and experiences, engagement and features, attrition and adherence, and app availability. We simultaneously conducted a search on the U.S. Google Play and the U.S. Apple App Store for apps denoted in the research literature and other commercially available apps.</div></div><div><h3>Results</h3><div>The academic literature search yielded 3753 articles, of which 34 were included. Across these 34 studies, 32 unique apps related to schizophrenia and psychosis were featured. A search of the U.S. app marketplaces yielded only one relevant app peer-reviewed in the last decade and that was broadly accessible to patients.</div></div><div><h3>Conclusion</h3><div>To realize the full clinical utility of these apps, it is essential to shift the focus toward their specific features and functionalities, supported by more rigorous research and follow-up studies. There is a pressing need for greater standardization in outcome measures and record-keeping practices to ensure consistency and reliability across the field. While the number of commercially available apps has increased, the lack of robust, large-scale controlled studies and standardized controls has resulted in inconsistent findings. Findings highlight the importance of conducting more controlled studies and randomized clinical trials with appropriate controls to strengthen the evidence base and guide the effective implementation of digital health interventions in mental health care.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"285 ","pages":"Pages 204-214"},"PeriodicalIF":3.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145220360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Psychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months” [Schizophr. Res. volume 276 (2025), 8–14/article number] “精神病理轨迹和首次发作精神分裂症的复发与24个月以上的长效注射依从性”的更正[精神分裂症。Res.第276卷（2025），8-14/条数]。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 DOI: 10.1016/j.schres.2025.04.005

Smit Retha, Luckhoff Hilmar, Phahladira Lebogang, Kilian Sanja, Emsley Robin, Asmal Laila

引用次数: 0

Corrigendum to “Sleep oscillations and their relations with sleep-dependent memory consolidation in early course psychosis and first-degree relatives” [Schizophr. Res. 274 (2024) 473–485] “睡眠振荡及其与早期精神病和一级亲属睡眠依赖性记忆巩固的关系”的勘误表[精神分裂症]。[Res. 274(2024) 473-485]。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 DOI: 10.1016/j.schres.2025.03.030

Dan Denis , Bengi Baran , Dimitrios Mylonas , Courtney Spitzer , Nicolas Raymond , Christine Talbot , Erin Kohnke , Olivia Larson , Robert Stickgold , Matcheri Keshavan , Dara S. Manoach

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Schizophrenia Research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀